What is PaxMedica Financial Strength?
PaxMedica has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
PaxMedica has no long-term debt (1).
As of today, PaxMedica's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of PaxMedica's Financial Strength
For the Biotechnology subindustry, PaxMedica's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PaxMedica's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PaxMedica's Financial Strength distribution charts can be found below:
* The bar in red indicates where PaxMedica's Financial Strength falls into.
PaxMedica Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
PaxMedica's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-3.69 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.
PaxMedica's Interest Coverage for the quarter that ended in Mar. 2024 is
| PaxMedica had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
PaxMedica's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
PaxMedica has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PaxMedica (PaxMedica) Business Description
Traded in Other Exchanges
N/A
Address
303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
Executives
| Zachary Rome |
director, officer: Chief Operating Officer |
C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008 |
| Michael Derby |
director, officer: Executive Chairman |
303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591 |
| Howard J. Weisman |
director, officer: Chief Executive Officer |
C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008 |
| Karen Larochelle |
director |
900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008 |
| John F Coelho |
director |
22 BENEDICT CRESCENT, BASKING RIDGE NJ 07920 |
| Charles J Casamento |
director |
99 BELBROOK WAY, ATHERTON CA 94027 |
| David W. Hough |
officer: Chief Medical Officer |
C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008 |
| Tardimed Sciences Llc |
10 percent owner |
303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591 |
| Stephen Sheldon |
officer: Chief Financial Officer |
2 REVOLUTIONARY WAY, #312, HOPKINTON MA 01748 |
PaxMedica (PaxMedica) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PXMD has been successfully added to your